MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s13148-025-01987-w

Медицинская библиотека · Clinical epigenetics · 2025

Phase II study of dual epigenetic targeting with chidamide and azacitidine in patients with high-risk acute myeloid leukemia after allo-HSCT.

Wu Ya-Xue, Wan Chao-Ling, Tan Kai-Wen, Zhang Yang, Zhang Yan-Ming, Zhang Hao, Wu De-Pei, Chen Su-Ning, Wang Ying, Ma Xiao, Dai Hai-Ping, Qian Chong-Sheng, Jiang Shan-Shan, Bao Hai-Yan, Hu Xiao-Hui, Li Zheng, Xue Sheng-Li

СтатьяКлиническое исследование II фазыМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is potentially the only curative option for high-risk acute myeloid leukemia (AML) patients. However, disease relapse remains the principal cause of treatment failure of these patients, and outcomes of salvage treatments are poor. This research seeks to evaluate the efficacy and safety of a dual epigenetic targeting maintenance therapy with chidamide and azacitidine (AZA) in patients with high-risk AML post-allo-HSCT.

METHODS

This multicenter, open-label, phase 2 prospective clinical trial (ChiCTR2300067593) recruited and followed up 48 patients diagnosed with high-risk AML post-allo-HSCT from 3 hospitals in China from November 2021 to March 2024. Chidamide (5 mg) was administered orally once daily for 5 days, combined with AZA (75 mg/m2) subcutaneously daily for 5 days, respectively. Treatment started as early as 3 months after transplantation. All patients were in complete remission before each maintenance cycle. A total of 6 cycles was recommended.

RESULTS

The 2-year cumulative incidence of relapse (CIR) was 8.4% (95% CI 4.4-12.4%), 2-year relapse-free survival (RFS) was 91.6% (95% CI 87.6-95.6%), and overall survival (OS) was 97.9% (95% CI 95.8-100%). At the end of the follow-up period, 4 patients relapsed, of which 1 patient died of leukemia recurrence; the other three patients underwent second allo-HSCT and are still alive in remission. The most common adverse events (AEs) were hematological toxicity. No grade > 3 AEs were noted. Graft-versus-host disease (GVHD) occurred in 29.2% (14/48) of patients. Six cases (6/48, 12.5%) were complicated with infection. No treatment-related mortality occurred.

CONCLUSIONS

Dual epigenetic targeting maintenance treatment with CHI-AZA has an acceptable toxicity profile and might potentially be effective to prevent relapse in high-risk AML patients after allo-HSCT.

TRIAL REGISTRATION: ClinicalTrials.gov, ChiCTR2300067593. Registered January 12, 2013.

Для цитирования: Wu Ya-Xue, Wan Chao-Ling, Tan Kai-Wen, Zhang Yang, Zhang Yan-Ming, Zhang Hao, Wu De-Pei, Chen Su-Ning, Wang Ying, Ma Xiao, Dai Hai-Ping, Qian Chong-Sheng, Jiang Shan-Shan, Bao Hai-Yan, Hu Xiao-Hui, Li Zheng, Xue Sheng-Li. Phase II study of dual epigenetic targeting with chidamide and azacitidine in patients with high-risk acute myeloid leukemia after allo-HSCT.. Clinical epigenetics. 2025. DOI: 10.1186/s13148-025-01987-w.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.